StemCell Therapy

Dec. 3, 2019 14:48 UTC

BOSTON--(BUSINESS WIRE)-- Today, InvicroLLC, a Konica Minolta Company, has joined Accentures open partner ecosystemthe INTIENT Networkwhich is designed to help solution providers, software vendors and life sciences companies team more effectively to accelerate drug discovery and improve patient outcomes. Invicro is a global provider of imaging biomarkers, core lab services, advanced analytics and software solutions for drug discovery and development.

The INTIENT Network is an integral part of INTIENT Research, Accentures cloud-based informatics suite that is focused on improving productivity, efficiency and innovation in the drug discovery process. Accenture is currently working with a select number of independent software vendors and organizations, including Invicro, to integrate their technology and content into the INTIENT platform.

Through the INTIENT Network, research scientists can access Invicros industry-leading imaging software platforms, iPACS and VivoQuant, that help transform the way translational medicine research is conducted. Invicro joining the network contributes to a robust ecosystemone that offers the most advanced, cloud-based informatics solutions to help accelerate precision medicine studies across all therapeutic areas.

By providing access to Invicros novel software solutions, researchers will easily gain insights from complex biological data at each drug discovery and development phase, stated Mr. Chris Fuller, Vice President of Software for Invicro. The advanced and collaborative capabilities offered by Invicro and Accenture will improve operational efficiencies and help streamline drug discovery efforts by using a data-driven approach.

Invicros capabilities will be available to life sciences companies within a common informatics framework that handles core infrastructure requirements such as data ingestion and cleansing, security and IP management, request management workflow, enterprise search, data governance, and collaboration environments.

Imaging data is enabling some incredible opportunities in early drug discovery, yet there remain challenges around the effective image management, interpretation, and sharing, said Joe Donahue, managing director, Accenture Life Sciences. I look forward to working closely with Invicro to leverage their capabilities to help address these challenges which will, ultimately, lead to better outcomes for patients.

About Invicro Headquartered in Boston, MA, Invicro was founded in 2008 and today has offices, laboratories and clinics around the world, from coast-to-coast within the United States, to Europe and Asia that support leading pharmaceutical and biotechnology companies and top research universities. Invicros multi-disciplinary team provides solutions to help enhance the discovery and development of life-changing drugs across all stages of the drug development pipeline (Phase 0-IV), leveraging all imaging modalities within a broad scope of therapeutic areas, including neurology, oncology, cardiology, and pulmonary. Invicros quantitative biomarker services, advanced analytics tools, and clinical operational services are backed by their industry-leading software informatics platforms, VivoQuant and iPACS.

Invicro is a Konica Minolta company and part of their precision medicine initiative, which aims to accelerate personalized medicine, discover novel therapeutic targets and develop innovative therapeutic technologies for unmet medical needs. Along with their sister company Ambry Genetics, Invicro develops and leverages the latest approaches in quantitative biomarkers including imaging, quantitative pathology and genomics. Visit http://www.invicro.com for more information

About Konica Minolta Konica Minolta, Inc. (Konica Minolta) is a global digital technology company with core strengths in imaging and data analysis, optics, materials, and nano-fabrication. Through innovation, Konica Minolta creates products and digital solutions for the betterment of business and societytoday and for generations to come. Across its Business Technologies, Healthcare, and Industrial-facing businesses, the company aspires to be an Integral Value Provider that applies the full range of its expertise to offer comprehensive solutions to the customers most pressing problems, works with the partners to ensure the solutions are sustainable, anticipates and addresses tomorrows issues, and tailors each solution to meet the unique and specific needs of its valued customers. Leveraging these capabilities, Konica Minolta contributes to productivity improvement and workflow change for its customers and provides leading-edge service solutions in the IoT era. Headquartered in Tokyo and with operations in more than 50 countries, Konica Minolta has more than 43,000 employees serving approximately two million customers in over 150 countries. Konica Minolta is listed on the Tokyo Stock Exchange, (TSE4902). For further information, visit: https://www.konicaminolta.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191203005690/en/

Read the original post:
Invicro LLC Joins Accenture's INTIENT Network to Help Advance Innovation in Drug Discovery and Scientific Research - BioSpace

This entry was posted on December 3, 2019 at 6:42 pm and is filed under Nano medicine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |